Loading company…
Sengenics develops autoantibody biomarker signatures and biochip tests for health research and screening.
Founded in 1996 and based in Singapore, Sengenics is a functional proteomics company. It develops autoantibody biomarker signatures for drug development in cancer immunotherapy and other diseases, as well as a biochip test for COVID-19 and SARS-CoV-2 screening.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in